TASK Eden
Welcome,         Profile    Billing    Logout  
 8 Trials 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Diacon, Andreas
Sisonke Boost, NCT05148845: Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Recruiting
3b
500000
RoW
Booster vaccine
Wits Health Consortium (Pty) Ltd, National Department of Health of South Africa, National Institute of Communicable Diseases - NICD, KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP, Fred Hutchinson Cancer Center, Hutchinson Center Research Institute of South Africa (HCRISA), Janssen Vaccines & Prevention B.V., Bio Analytical Research Corporation, Dis-Chem Pharmacy, BioVac, Biocair, Right to Care, Clinical Laboratory Services, Institute of Infectious Disease and Molecular Medicine
SARS CoV 2 Infection
01/22
06/23
NCT05896930: Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

Completed
2
134
RoW
Meropenem 6g IV over 6 hours, Ertapenem 1g IM, Meropenem 3g IV, Ertapenem 1g IV, Amoxicillin/CA twice daily, Rifampicin 35 mg/kg, Meropenem 6g IV over 60 minutes, Rifafour e-275, Meropenem 4g IV, Amoxicillin/CA once daily
TASK Applied Science
Pulmonary Tuberculosis
01/21
01/21
NCT04621825: Post Market Surveillance Study to Confirm Safety and Performance of Silicone PHMB Foam

Completed
N/A
187
RoW
ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.
Advanced Medical Solutions Ltd., Imarc Research, Inc.
Wound
05/24
07/24
Rassool, Mohammed Siddique
PRACTECAL-EE, NCT04207112: Economic Evaluation of New MDR TB Regimens

Completed
2/3
73
RoW
Bedaquiline, Sirturo, R207910, TMC207, Pretomanid, PA-824, Moxifloxacin, Avelox, BAY 12-8039, Linezolid, Zyvox, Clofazimine, Lamprene, Standard Drugs
Medecins Sans Frontieres, Netherlands, London School of Hygiene and Tropical Medicine, Ministry of Health, Republic of Uzbekistan, Ministry of Public Health, Republic of Belarus, THINK TB & HIV Investigative Network, University of Liverpool, Wits Health Consortium (Pty) Ltd
Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculoses
08/22
08/22
PRACTECAL-PRO, NCT03942354: Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

Completed
2/3
137
RoW
Bedaquiline, Sirturo, R207910, TMC207, Pretomanid, PA-824, Moxifloxacin, Avelox, BAY 12-8039, Linezolid, Zyvox, Clofazimine, Lamprene, Directly observed therapy (DOT)
Medecins Sans Frontieres, Netherlands, University of Sussex, London School of Hygiene and Tropical Medicine, THINK TB & HIV Investigative Network, Wits Health Consortium (Pty) Ltd, Ministry of Public Health, Republic of Belarus, Ministry of Health, Republic of Uzbekistan
Multidrug Resistant Tuberculosis
05/22
05/22
panTB-HM, NCT05686356: A Pan-TB Regimen Targeting Host and Microbe

Recruiting
2/3
352
RoW
Sutezolid, N-acetyl cysteine, NAC, Pretomanid, Bedaquiline, Rifafour
The Aurum Institute NPC, Ludwig-Maximilians - University of Munich, Stichting Katholieke Universiteit, Wits Health Consortium (Pty) Ltd, Instituto Nacional de Saúde, Mozambique, National Institute for Medical Research, Tanzania, University of Stellenbosch, Sequella, Inc., Global Alliance for TB Drug Development
Tuberculosis
09/25
09/25
NCT05221502: Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Completed
2
122
RoW
Delamanid + Bedaquiline + OPC-167832 10 mg, Delamanid + Bedaquiline + OPC-167832 30 mg, Delamanid + Bedaquiline + OPC-167832 90 mg, RHEZ
Otsuka Pharmaceutical Development & Commercialization, Inc., Bill and Melinda Gates Foundation
Pulmonary TB
04/24
05/24
Contact, See Central
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
NCT05547087: A Dose Finding Study of VN-0200

Completed
2
342
Japan
VN-0200
Daiichi Sankyo
Respiratory Syncytial Virus Infections
04/23
02/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Europe, Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Active, not recruiting
2
21
Japan
Pexidartinib, TURALIO™, PLX3397
Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor
03/23
05/26
IDeate-Pantumor 01, NCT04145622: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Hourglass Sep 2024 - Sep 2024 : Updated data for adv solid tumors
Recruiting
1/2
250
Japan, US
Ifinatamab deruxtecan (I-DXd)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Malignant Solid Tumor
12/25
03/27
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Recruiting
1/2
120
US, RoW
Q702, Pembrolizumab, KEYTRUDA®
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
10/25
06/26
KEYNOTE-E45, NCT05394103: Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Recruiting
1/2
130
US, RoW
Q901, KEYTRUDA® (pembrolizumab)
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
12/25
08/26
DS3939-077, NCT05875168: First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Recruiting
1/2
430
Europe, Japan, US
DS-3939a
Daiichi Sankyo
Advanced Solid Tumor, Metastatic Solid Tumor
03/26
07/27
U31402-A-U102, NCT03260491: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Checkmark Data from trial for NSCLC
Jan 2021 - Jan 2021: Data from trial for NSCLC
Checkmark Data from trial for EGFRm NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from trial for EGFRm NSCLC at ESMO 2020
Recruiting
1
309
Europe, Japan, US, RoW
HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
03/26
12/26
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor

Active, not recruiting
1
78
US
Q702
Qurient Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Cancer
12/24
02/25
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Jan 2024 - Dec 2024: Data from TROPION-Lung02 trial for advanced or metastatic NSCLC
Checkmark Interim analysis data from TROPION-Lung02 trial for NSCLC
Aug 2022 - Aug 2022: Interim analysis data from TROPION-Lung02 trial for NSCLC
Active, not recruiting
1
145
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
06/25
06/25
NCT04419532: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Recruiting
1
40
Canada, Japan, US
DS-1055a
Daiichi Sankyo Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
06/25
06/25
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting
1
280
Japan, US, RoW
HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
06/25
02/26
DS1471-079, NCT06074705: A Study of DS-1471a In Subjects With Advanced Solid Tumors

Recruiting
1
80
Japan
DS-1471a
Daiichi Sankyo Co., Ltd.
Advanced Solid Tumor
06/27
06/27
NCT05769764: A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Completed
N/A
225
US
Archival tissue specimen and immunohistochemistry staining
Daiichi Sankyo, Inc.
Non-small Cell Lung Cancer
04/23
04/23
Leader, CRS
HVTN 135, NCT04607408: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Completed
1
38
RoW
CH505TF gp120, GLA-SE adjuvant, Placebo
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
07/24
07/24
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Active, not recruiting
N/A
13
RoW
Analytical Treatment Interruption
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
02/25
02/25
McHarry, Kirsten R
NOVATION-1, NCT04669015: Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19

Recruiting
3
914
Canada, RoW
Novaferon, Standard of Care, Placebo
Genova Inc.
Covid19
08/22
08/22
Botha, Louis
panTB-HM, NCT05686356: A Pan-TB Regimen Targeting Host and Microbe

Recruiting
2/3
352
RoW
Sutezolid, N-acetyl cysteine, NAC, Pretomanid, Bedaquiline, Rifafour
The Aurum Institute NPC, Ludwig-Maximilians - University of Munich, Stichting Katholieke Universiteit, Wits Health Consortium (Pty) Ltd, Instituto Nacional de Saúde, Mozambique, National Institute for Medical Research, Tanzania, University of Stellenbosch, Sequella, Inc., Global Alliance for TB Drug Development
Tuberculosis
09/25
09/25
DECISION, NCT05926466: BTZ-043 Dose Evaluation in Combination and Selection

Recruiting
2
90
RoW
BTZ-043, Bedaquiline, SIRTURO®, Delamanid, OPC-67683, Deltyba, Moxifloxacin, Lonxave
Michael Hoelscher, Radboud University Medical Center, University of California, San Francisco, University College, London
Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis
08/24
08/24
PARADIGM4TB, NCT06114628: Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting
2
2500
RoW
GSK3036656, BTZ-043, Bedaquiline (B), Delamanid (D), Pretomanid (Pa), Moxifloxacin (M), Linezolid (L), Pyrazinamide (Z), Rifampicin (R), Isoniazid (H), Ethambutol (E)
University College, London, Radboud University Medical Center, London School of Hygiene and Tropical Medicine, University of Oxford, Research Center Borstel, Lygature, TASK Applied Science, Vita-Salute San Raffaele University, Helmholtz Zentrum Munchen, KNCV Tuberculosis Foundation, Critical Path Institute, European Lung Foundation, Instituto de Saude Publica da Universidade do Porto, University of Liverpool, Institut de Recherche Pour le Developpment, University of Hamburg-Eppendorf, University of California, San Francisco, TB Alliance, Find, University of Milano, University of St Andrews, Uppsala University, European Respiratory Society, Tuberculosis Network European Trialsgroup, Janssen, LP, Otsuka Pharmaceutical Development & Commercialization, Inc., German Center for Infection Research, LMU University Hospital Munich, University of Cambridge, GlaxoSmithKline
Pulmonary Tuberculosis
02/27
08/27
Nell, Marlene
NCT06058299: Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis

Active, not recruiting
2
309
RoW
TBAJ-876, Pretomanid, PA-824, Dovprela, Linezolid, Zyvox, Bedaquiline, Sirturo, TMC207, HRZE, HR
Global Alliance for TB Drug Development
Pulmonary TB, Pulmonary Tuberculosis, Drug Sensitive Tuberculosis
01/25
06/26

Download Options